Expert Interviews

Roy Fleischmann, MD: Safety of JAK Inhibitors

July 27, 2021

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Richard Furie, MD: Safety and Efficacy of BIIB059 for Systemic Lupus Erythematosus

July 09, 2021

Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.

Andrew L Concoff, MD, FACR, CAQSM: Value-Based Care

June 29, 2021

Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.

Gene Therapy Improves Pain Management and Disease Progression for Osteoarthritis

June 24, 2021

Treatment of the osteoarthritis has been at a standstill, with short-term pain management with steroid injections considered standard care. However, a promising new therapeutic approach may help to sustain pain relief over time.

Mehret Birru Talabi, MD, PhD: Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis

June 17, 2021

Rheumatology Network sat down with Mehret Birru Talabi, MD, PhD, to discuss the recent study published in ACR Open Rheumatology entitled, “Tough choices: Exploring medication decision-making during pregnancy and lactation among women with inflammatory arthritis.”

Alexis Ogdie, MD: Importance of Patient Experience in Psoriatic Arthritis Treatment

June 14, 2021

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Eugen Feist, MD: Olokizumab Emerges as Promising Therapy for Rheumatoid Arthritis

June 10, 2021

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.